|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
¶ – Release Delayed to: 2/26/20 ·As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/20/19 AnPac Bio-Medical Science Co, Ltd DRSLTR¶ 2/26/20 1:68K Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: DRSLTR Comment-Response or Draft-Registration-Statement HTML 12K
Letter to the SEC
| DRSLTR |
Confidential
Draft Registration Statement
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
USA
| Re: | AnPac Bio-Medical Science Co., Ltd. |
| Confidential Submission of the Draft Registration Statement on Form F-1 |
Dear Sir/Madam,
On behalf of our client, AnPac Bio-Medical Science Co., Ltd., a foreign private issuer organized under the laws of the British Virgin Islands (the “Company”), we are hereby submitting a draft registration statement on Form F-1 (the “Draft Registration Statement”) relating to a proposed initial public offering in the United States of the Company’s ordinary shares, par value US$1 per share, to be represented by American depositary shares (“ADSs”) via EDGAR to the Securities and Exchange Commission (the “Commission”) for confidential review pursuant to the Jumpstart Our Business Startups Act, as amended (the “JOBS Act”). The Company confirms that it is an “emerging growth company” as defined in the JOBS Act and its securities have not been previously sold pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Securities Act”). A registration statement on Form F-6 relating to the ADSs will be filed with the Commission in due course.
Financial Statements
The Company has included in the Draft Registration Statement its audited consolidated financial statements as of and for the fiscal years ended December 31, 2017 and 2018. As an emerging growth company, the Company has omitted its financial statements for the fiscal year ended December 31, 2016 and selected financial information for the fiscal years before January 1, 2017. The Company plans to include the financial statements as of and for the nine months ended September 30, 2018 and 2019 in subsequent filings for the initial public offering.
* * *
Securities and Exchange Commission
Page 2 of 2
If you have any questions regarding the Draft Registration Statement, please contact the undersigned by phone at +852-2532-3783 or via e-mail at szhao@cgsh.com, or Dr. Chris Yu, the founder, chairman and chief executive officer of AnPac Bio-Medical Science Co., Ltd., by telephone at +86-21-51085515-888 or via e-mail at chris_yu@anpac.cn, or Pavel Gu, the partner at Ernst & Young Hua Ming LLP, by telephone at +86-21-2228-4063 or via email at pavel.gu@cn.ey.com. Ernst & Young Hua Ming LLP is the independent registered public accounting firm of the Company.
| Very truly yours, | ||
| CLEARY GOTTLIEB STEEN & HAMILTON LLP | ||
| By: | /s/ Shuang ZHAO | |
| Shuang ZHAO, a Partner | ||
| cc: | Dr. Chris Yu, Founder, Chairman and Chief Executive Officer, AnPac Bio-Medical Science Co., Ltd. |
| Richard A. Friedman, Partner, Sheppard Mullin Richter & Hampton LLP |
| Stephen A. Cohen, Partner, Sheppard Mullin Richter & Hampton LLP |
| Pavel Gu, Partner, Ernst & Young Hua Ming LLP |
| This ‘DRSLTR’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Release Delayed to: | 2/26/20 | UPLOAD | ||
| 9/30/19 | ||||
| Filed on: | 9/20/19 | DRS | ||
| 12/31/18 | ||||
| 9/30/18 | ||||
| 12/31/17 | ||||
| 1/1/17 | ||||
| 12/31/16 | ||||
| List all Filings | ||||